Literature DB >> 11693463

Endometriosis: aetiology, pathogenesis and treatment.

T J Child1, S L Tan.   

Abstract

Endometriosis, which may be defined as the presence and proliferation of endometrial tissue outside the uterine cavity, causes pain and infertility for millions of women worldwide. Studies suggest a prevalence of 0.5 to 5% in fertile and 25 to 40% in infertile women. The most widely accepted aetiological theory is that retrograde flow of menstrual fluid through the Fallopian tubes deposits viable endometrial tissue, which implants on the peritoneal surface. Increasingly, the aetiology of endometriosis is being studied at the immunological and genetic levels. The aim of treatment of endometriosis is to remove or diminish disease deposits. This may be attempted through medical or surgical means. It has long been recognised that endometriotic glands are hormonally sensitive. Medical therapies work by inducing a hypoestrogenic, anovulatory state to induce atrophy within the glandular tissue. Conception is generally not possible during medical therapy and has not been demonstrated to increase afterwards. Medical treatment of endometriosis should be discouraged when infertility is the primary problem. In this situation surgery or an assisted reproduction treatment such as in vitro fertilisation may be more appropriate. Medical treatment of pain caused by endometriosis is generally effective. There is little difference in efficacy between the different medications but their adverse effect profiles differ greatly. It appears that gonadotropin-releasing hormone agonists, particularly when used with add-back estrogen, may be more acceptable to women than other treatments. Laparoscopic surgical treatment of minimal and mild endometriosis has been demonstrated to increase fecundity. Surgical treatment has also been shown to decrease pain scores compared with expectant management. Ongoing and future research examining the aetiology of endometriosis at the immunological and genetic levels should usher in new treatments directed at the actual cause of the disease. More randomised trials examining the role of surgery, and comparing surgical and medical treatments, are also required and are necessary if we are to continue in our attempts to adopt an evidence-based approach to treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11693463     DOI: 10.2165/00003495-200161120-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  47 in total

1.  Laser laparoscopic adhesiolysis.

Authors:  C Sutton; R MacDonald
Journal:  J Gynecol Surg       Date:  1990

2.  Factors that affect outcome of in-vitro fertilisation treatment.

Authors:  A Templeton; J K Morris; W Parslow
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

3.  The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization.

Authors:  S L Tan; C Kingsland; S Campbell; C Mills; J Bradfield; N Alexander; J Yovich; H S Jacobs
Journal:  Fertil Steril       Date:  1992-04       Impact factor: 7.329

4.  Magnetic resonance imaging of pelvic endometriosis.

Authors:  R Manfredi; A L Valentini
Journal:  Rays       Date:  1998 Oct-Dec

5.  Endometriosis is not detrimental to embryo implantation in oocyte recipients.

Authors:  L Sung; T Mukherjee; T Takeshige; M Bustillo; A B Copperman
Journal:  J Assist Reprod Genet       Date:  1997-03       Impact factor: 3.412

6.  Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group.

Authors: 
Journal:  Fertil Steril       Date:  1996-12       Impact factor: 7.329

7.  Artificial insemination by husband in unexplained infertility compared with infertility associated with peritoneal endometriosis.

Authors:  A K Omland; T Tanbo; P O Dale; T Abyholm
Journal:  Hum Reprod       Date:  1998-09       Impact factor: 6.918

8.  Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin.

Authors:  S L Tan; N Maconochie; P Doyle; S Campbell; A Balen; J Bekir; P Brinsden; R G Edwards; H S Jacobs
Journal:  Am J Obstet Gynecol       Date:  1994-08       Impact factor: 8.661

9.  Incidence of pelvic endometriosis in Rochester, Minnesota, 1970-1979.

Authors:  D E Houston; K L Noller; L J Melton; B J Selwyn; R J Hardy
Journal:  Am J Epidemiol       Date:  1987-06       Impact factor: 4.897

10.  A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.

Authors:  P Vercellini; L Trespidi; A Colombo; N Vendola; M Marchini; P G Crosignani
Journal:  Fertil Steril       Date:  1993-07       Impact factor: 7.329

View more
  18 in total

Review 1.  Managing the misplaced: approach to endometriosis.

Authors:  Bethany Jackson; Deanna E Telner
Journal:  Can Fam Physician       Date:  2006-11       Impact factor: 3.275

2.  Single-nucleotide polymorphisms in the lysyl oxidase-like protein 4 and complement component 3 genes are associated with increased risk for endometriosis and endometriosis-associated infertility.

Authors:  Lynnette A Ruiz; Julie Dutil; Abigail Ruiz; Jessica Fourquet; Sonia Abac; Joaquín Laboy; Idhaliz Flores
Journal:  Fertil Steril       Date:  2011-07-05       Impact factor: 7.329

3.  Activated AKT pathway promotes establishment of endometriosis.

Authors:  Tae Hoon Kim; Yanni Yu; Lily Luo; John P Lydon; Jae-Wook Jeong; J Julie Kim
Journal:  Endocrinology       Date:  2014-02-26       Impact factor: 4.736

4.  Stress exacerbates endometriosis manifestations and inflammatory parameters in an animal model.

Authors:  Marielly Cuevas; Idhaliz Flores; Kenira J Thompson; Dinah L Ramos-Ortolaza; Annelyn Torres-Reveron; Caroline B Appleyard
Journal:  Reprod Sci       Date:  2012-04-23       Impact factor: 3.060

5.  Predictive biomarkers may allow precision therapy of endometriosis.

Authors:  Zhen Hou; Ramanaiah Mamillapalli; Hugh S Taylor
Journal:  J Endometr Pelvic Pain Disord       Date:  2017-08-11

6.  Increased AKT or MEK1/2 activity influences progesterone receptor levels and localization in endometriosis.

Authors:  Jennifer L Eaton; Kenji Unno; Marshall Caraveo; Zhenxiao Lu; J Julie Kim
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

7.  Endometriosis - morphology, clinical presentations and molecular pathology.

Authors:  Neha Agarwal; Arulselvi Subramanian
Journal:  J Lab Physicians       Date:  2010-01

8.  A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model.

Authors:  D Soysal; S Kızıldağ; B Saatlı; C Posacı; S Soysal; M Koyuncuoğlu; Öe Doğan
Journal:  Balkan J Med Genet       Date:  2015-04-10       Impact factor: 0.519

9.  CA-125 concentration in serum and peritoneal fluid in patients with endometriosis - preliminary results.

Authors:  Maria Szubert; Jacek Suzin; Tomasz Wierzbowski; Katarzyna Kowalczyk-Amico
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

10.  Asymmetric dimethylarginine (ADMA), nitric oxide metabolite, and estradiol levels in serum and peritoneal fluid in women with endometriosis.

Authors:  Maryam Kianpour; Mehdi Nematbakhsh; Sayad Mehdi Ahmadi
Journal:  Iran J Nurs Midwifery Res       Date:  2015 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.